Department of Anatomy, Faculty of Medicine and University Hospital, University of Champagne-Ardenne, Reims, France; School of Surgery of Nancy, University of Lorraine, Nancy, France; IADI, INSERM U1254, University of Lorraine, Nancy, France; Department of Digestive Surgery, Robert-Debre University Hospital, University of Champagne-Ardenne, Reims, France.
School of Surgery of Nancy, University of Lorraine, Nancy, France; IADI, INSERM U1254, University of Lorraine, Nancy, France.
Ann Anat. 2019 Sep;225:57-64. doi: 10.1016/j.aanat.2019.06.003. Epub 2019 Jul 5.
Pancreatic cancer is associated with a poor prognosis, mainly due to lymph node invasion and lymph node recurrence after surgical resection, even after extended lymphadenectomy. The peripancreatic lymphatic system is highly complex and the specific lymphatic drainage of each part of the pancreas has not been established. The aim of this study was to determine the lymphatic drainage pathways specific to each part of the pancreas on live pigs using Patent Blue. The pancreases of 14 live pigs were injected in different parts of the gland. The technique was efficient and reproducible. The diffusion patterns were similar for each location and were reported. Our results in pigs allowed us to define specific nodal relay stations and lymphatic drainage for each part of the pancreas and confirm that independent anatomical-surgical pancreatic segments can be described. It is interesting to note that lymphatic drainage for the upper part of the proximal part of pancreas (duodenal lobe) occurred on the left side of the portal vein. This suggests that lymph node resection during cephalic duodenopancreatectomy in humans should be extended to the left side of the mesenteric vein, and probably to the right side of the superior mesenteric artery, as recently suggested. These results could help surgeons perform safe anatomical-segmental pancreatic resections with accurate lymphadenectomies and improve survival in patients with pancreatic cancer. Based on these results we will perform an innovative prospective study. Patent Blue will be injected into different parts of the gland in patients operated for pancreatic resection, and lymphatic diffusion of the dye will be recorded in relation to their origin from the theoretical pancreatic segments (ClinicalTrials.gov Identifier: NCT03597230).
胰腺癌预后不良,主要与淋巴结侵犯以及手术切除后淋巴结复发有关,即使进行了扩大淋巴结清扫术也是如此。胰周淋巴系统非常复杂,胰腺各部分的具体淋巴引流尚未确定。本研究旨在使用专利蓝确定活猪胰腺各部分的特定淋巴引流途径。将 14 头活猪的胰腺在不同部位注射。该技术高效且可重复。每个部位的扩散模式相似,并进行了报道。我们在猪身上的结果使我们能够为胰腺的每个部分定义特定的淋巴结中继站和淋巴引流,并证实可以描述独立的解剖-手术胰腺段。有趣的是,胰头近端(十二指肠叶)上部的淋巴引流发生在门静脉的左侧。这表明在人类进行头侧胰十二指肠切除术时,淋巴结切除术应扩展到肠系膜静脉的左侧,可能还需要扩展到肠系膜上动脉的右侧,正如最近所建议的那样。这些结果可以帮助外科医生进行安全的解剖性节段性胰腺切除术,并提高胰腺癌患者的生存率。基于这些结果,我们将进行一项创新性的前瞻性研究。在接受胰腺切除术的患者中,将向不同的腺体部位注射专利蓝,并记录染料的淋巴扩散与理论胰腺段的起源(ClinicalTrials.gov 标识符:NCT03597230)之间的关系。